NEW YORK – Germantown, Maryland-based biopharmaceutical company Precigen said on Monday that it dosed the first patient in its Phase I/II trial investigating immunotherapy PRGN-2009 in HPV-positive solid tumors.
NEW YORK – Germantown, Maryland-based biopharmaceutical company Precigen said on Monday that it dosed the first patient in its Phase I/II trial investigating immunotherapy PRGN-2009 in HPV-positive solid tumors.
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.